Coller IP is pleased to welcome its latest recruit, Robert Gleave.
Robert joins Coller IP as an intellectual property consultant with extensive experience of research within the pharmaceutical sector and medicine. He has held roles leading the evaluation and initiation of early stage research programs and managing collaborations with universities and contract research organisations. Robert has in-depth understanding of the key role of intellectual property protection and strategy during the development of a research program, together with a detailed knowledge of prior art searching and IP landscaping.
Robert is working with clients to help them to develop strategies to protect their intangible assets, carry out investor due diligence and draft patent applications. Robert will also be applying his expertise in medicinal chemistry, including organic chemistry, biological screening, drug metabolism and pharmacokinetics, analytical and separation technologies, computational modelling and data visualisation, toxicity and physical property screening, biological target evaluation, lead molecule and clinical candidate selection.
Robert gained a chemistry degree from SouthamptonUniversity(MChem, 1st class) which included industrial experience in the agrochemicals sector. Since graduating, Robert has held a number of roles within the pharmaceutical industry including as a medicinal chemistry team leader within the Neurosciences Centre of Excellence for Drug Discovery at GlaxoSmithKline. Robert is a named author or inventor on more than thirty patent applications and scientific journal articles. He has additionally studied law at the Open University and is developing his understanding of a broad range of IP issues by studying towards a Post-graduate Certificate in Intellectual Property.